Introduction
============

Huntington\'s disease (HD) is caused by the expansion of a polymorphic CAG trinucleotide repeat in the first exon of the gene encoding huntingtin (Huntington\'s Disease Collaborative Research Group (HDCRG) [@b55]). Expression of mutant huntingtin protein (mHtt) leads to a characteristic triad of highly disabling motor, psychiatric, and cognitive symptoms that progress over several decades leading to death (Newcombe [@b78]; Adams et al. [@b1]; Roos et al. [@b93]; Foroud et al. [@b33]) Pharmacotherapy for HD patients is currently very limited and disease progression is relentless (reviewed in Ross et al. [@b94]). At the cellular level, expression of mHtt containing an expanded CAG repeat-encoded polyglutamine region in the amino terminus of the protein leads to a variety of changes in cellular function including transcriptional dysregulation (reviewed in Zuccato et al. [@b111]).

Because specific subsets of caudate and putamen neurons (CPu) are known to be particularly susceptible to cell death in HD, there has been an intense effort to define changes in gene expression in the basal ganglia and particularly the medium spiny projection neurons in the CPu (which is functionally equivalent to the striatum in rodents; Graveland et al. [@b44]; Vonsattel et al. [@b107]; Halliday et al. [@b45]). Further, the chorea, akinesia and dystonia that occur in HD suggest profound basal ganglia dysfunction. Early studies that looked at levels of individual mRNAs and proteins demonstrated that the levels of a subset of mRNA and proteins were altered when mHtt was expressed (Augood et al. [@b6]; Cha et al. [@b17]; Denovan-Wright and Robertson [@b24]; Glass et al. [@b42]). In addition, multiple microarray studies have reported profound and early transcriptional dysregulation in the basal ganglia of HD patients (Luthi-Carter et al. [@b69]; Desplats et al. [@b25]; Hodges et al. [@b49]). One hypothesis is that the amino terminus of mHtt either sequesters transcription factors or is incorporated into the preinitiation complex and interferes with transcription at the gene promoter. Given that changes in gene expression occur over decades, a second hypothesis is that early changes in gene expression influence later changes in gene expression (Li et al. [@b65]; Zhai et al. [@b110]; Hogel et al. [@b51]). Altered gene expression also occurs in a subset of genes in the cortex, which shows less neurodegeneration than the CPu but whose function is altered in HD, and in peripheral blood where these changes may be monitored as biomarkers of disease progression (Halliday et al. [@b45]; Denovan-Wright and Robertson [@b24]; Borovecki et al. [@b14]; Lovrecic et al. [@b67]).

The type 1 cannabinoid receptor (CB~1~, *CNR1*) and the dopamine (DA) receptor type 2 (D~R~D~2~, *DRD2*) are expressed at high levels in the basal ganglia relative to other brain regions (Gerfen et al. [@b39]; Mailleux and Vanderhaeghen [@b70]; Matyas et al. [@b73]; Pickel et al. [@b84]). CB~1~ and D~R~D~2~ regulate neuronal activity in the CPu, limbic system, and other regions of the brain as key components of the larger endocannabinoid system (ECS) and dopaminergic system (DAS), respectively (reviewed in Gerdeman and Fernandez-Ruiz [@b38]; El Khoury et al. [@b29]). Decreased expression of CB~1~ and D~R~D~2~ is one of the earliest and most reliable transcriptional changes that occur during HD pathogenesis (Richfield et al. [@b90]; Cha et al. [@b17]; Glass et al., 2004; Denovan-Wright and Robertson [@b24]). Given that the expression and activity of these receptors is dependent upon the tone of their respective systems, it is logical that the ligands, enzymes, and other receptors that make up the ECS and DAS would also be dysregulated during HD progression, either as a direct result of mHtt or as a secondary response to changes in CB~1~ or D~R~D~2~. For this reason, novel therapies that target ECS have generated significant interest as potential treatments for HD and existing therapies that target the DAS are currently being used to treat HD (Curtis et al. [@b22]; Dowie et al. [@b26], [@b27],[@b28]; Blázquez et al. [@b13]; Sagredo et al. [@b97]; Pidgeon and Rickards [@b85]).

The ECS regulates neurotransmission and cell excitability throughout the central nervous system (CNS) and regulates cellular metabolism and migration in nonneuronal cells (reviewed in Howlett et al. [@b53]; Pertwee et al. [@b83]). In the brain, presynaptic CB~1~ receptors are activated by endogenous (endo) cannabinoids, which are synthesized and released from the postsynaptic neuron following depolarization (Giuffrida et al. [@b41]; Kreitzer and Regher [@b60]). In the CNS, the type 2 cannabinoid receptor (CB~2~, *CNR2*) is predominantly expressed in glial cells and is thought to inhibit proinflammatory processes (Atwood and Mackie, 2010; Lopez-Rodriguez et al. [@b66]). In addition to CB~1~ and CB~2~, the ECS is made up of putative cannabinoid receptors GPR18, and GPR119, the cation-permeable transient receptor potential vanilloid 1 (TRPV1), the anabolic enzymes diacyl glycerol lipase (DAGL), and *N*-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), the catabolic enzymes abhydrolase domain-containing protein 4 (ABDH4)*,* 6 (ABDH6)*,* 12 (ABDH12)*,* fatty acid amide hydrolase (FAAH), monoacyl glycerol lipase (MGLL), *N*-acylethanolamine acid amidase (NAAA), and the phosphatases Protein tyrosine phosphatase, nonreceptor type 22 (PTPN22) and Glycerophosphodiester phosphodiesterase 1 (GDE1), and the endocannabinoids (reviewed in Howlett et al. [@b53]; Pertwee et al. [@b83]). The most abundant endocannabinoids are anandamide (AEA) and 2-arachidonyl glycerol (2-AG; Martin et al. [@b71]). Endocannabinoids activate the nuclear receptor peroxisome proliferator-activated receptor *α* (PPAR*α*), which mediates many of the biological effects of cannabinoids including anti-inflammatory actions, feeding behavior, and analgesia (O\'Sullivan [@b81]). Endocannabinoid levels can be regulated by cyclooxygenase 2 (COX-2, *PTGS2*) during inflammation (Hermanson et al. [@b48]). Finally, strong evidence suggests that another putative cannabinoid receptor, GPR55, is also part of the ECS (Henstridge [@b46]).

Dopamine is involved in the regulation of motor activity and coordination, cognition, motivation and emotion in the basal ganglia, as well as in many other regions of the brain (Nieoullon [@b80]; Cools [@b20]). In this study, we defined the DAS is the widest possible sense, including the G protein-coupled dopamine receptors types 1--5 (D~R~D~1-5~), anabolic enzymes in the DA synthesis pathway such as phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and DOPA decarboxylase (DDC), catabolic enzymes such as monoamine oxidase A (MAOA) and B (MAOB)*,* and catechol-[o]{.smallcaps}-methyl transferase (COMT), and membrane channels such as the vesicular monoamine transporter (VMAT2, *SLC18A2*) and the dopamine transporter (DAT, *SLC6A3*; reviewed in Smith and Villalba [@b98]). Noradrenergic and adrenergic neurons, but not dopaminergic neurons, contain the enzyme dopamine *β*-hydroxylase (DBH) that converts DA to norepinephrine. Finally, the dopamine and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32, *PPP1R1B*) is activated via D~R~D~1/2~-mediated cAMP accumulation and is known to be downregulated in the medium spiny projection neurons of HD patients (Bibb et al. [@b12]; van Dellen et al. [@b23]; Spires et al. [@b101]). Together these proteins represent the regulators, effectors, and transducers of information for the DAS.

The purpose of this study was to determine which changes in the ECS and DAS have been consistently observed over multiple microarray studies of HD progression using a meta-analytical approach. As with all systematic analyses, this study used defined criteria to investigate, collate, and assess a large number of independent studies in order that the data might be assembled to generate novel perspectives and hypotheses. The methods used employed a mathematical algorithm to collate biological data across multiple quantitative studies (Kalathur et al. [@b58]). Using this weighted sums approach we were able to estimate effect size (Kalathur et al. [@b58]). The approach resembled a random effects model of meta-analysis, which is a model commonly applied to heterogeneous data. Our aims were (1) to determine which changes in gene expression were consistently observed in independent studies; (2) to determine whether changes in gene expression occurred consistently in different models of HD; (3) to compare the patterns of gene expression in mouse and in vitro models of HD to changes observed in human tissue; (4) to determine how changes in gene expression in the CNS compared to that of the periphery; and (5) to determine the temporal pattern of gene expression during disease progression. To do this, microarray data were collected from the Gene Expression Omnibus (GEO[@b35]), Gene Expression Omnibus Datasets (GEO Datasets[@b36]), Gene Expression Omnibus Profiles (GEO Profiles[@b37]). Profiles database. Ultimately, our goal was to relate the systems-wide changes in gene expression that occur in the ECS and DAS during HD progression to the potential therapeutic targeting of the ECS and DAS for HD.

Materials and Methods
=====================

Databases, search pipeline, exclusion and inclusion criteria
------------------------------------------------------------

We conducted a meta-analysis of differential gene expression in the ECS and DAS, using published microarray data, according to the guidelines described in (Kalathur et al. [@b58]). The components of the ECS and DAS were chosen based on existing literature and are described in Table[1](#tbl1){ref-type="table"}. Computerized literature searches were conducted across the following four databases: MED-LINE, EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials. To ensure that the widest possible range of studies were included, the search terms used were: "Huntington\*" and "\*array," "gene expression," or "differential\*" (Pidgeon and Rickards [@b85]). The preliminary search generated 204 results and was subsequently limited to English language papers published after 2000. Further exclusion criteria included reviews, editorials, commentaries, and letters to the editors of scientific journals. We applied the following additional exclusion criteria to ensure only relevant studies were included in the analysis: studies using nongenetic models of HD (e.g., lesion models), studies solely examining epigenetic changes or changes in the expression of noncoding RNAs, and studies that did not comply with the MIAME standards (Brazma et al. [@b15]; Spellman et al. [@b100]; Kalathur et al. [@b58]). Following the application of exclusion criteria, and removal of unrelated and duplicate papers, 39 results remained (Table[2](#tbl2){ref-type="table"}). Datasets from six additional studies were excluded from our results because they were not available through publicly available sources. Qualitative post-hoc comparisons were made between the findings of these studies and the datasets included in our quantitative meta-analysis (Luthi-Carter et al. [@b68]; Chan et al. [@b18]; Glass et al. [@b43]; Kuhn et al. [@b61]; Benn et al. [@b10]; Dowie et al. [@b28]).

###### 

Genes examined in this work.

  Endocannabinoid system   Dopaminergic system                                                                       
  ------------------------ ------------------------------------------------------------------------------- --------- --------------------------------------------------------------
  ABDH4                    Abhydrolase domain-containing Protein 4                                         COMT      Catechol-[o]{.smallcaps}-methyl transferase
  ABDH6                    Abhydrolase domain-containing protein 6                                         DBH       Dopamine *β*-hydroxylase
  ABDH12                   Abhydrolase domain-containing protein 12                                        DDC       DOPA decarboxylase
  DAGL                     Diacyl glycerol lipase                                                          DRD1      Dopamine receptor type 1
  CNR1                     Cannabinoid receptor type 1                                                     DRD2      Dopamine receptor type 2
  CNR2                     Cannabinoid receptor type 2                                                     DRD3      Dopamine receptor type 3
  FAAH                     Fatty acid amide hydrolase                                                      DRD4      Dopamine receptor type 4
  GDE1                     Glycerophosphodiester phosphodiesterase 1                                       DRD5      Dopamine receptor type 5
  GPR55                    G protein-coupled receptor 55                                                   MAOA      Monoamine oxidase A
  GPR119                   G protein-coupled receptor 119                                                  MAOB      Monoamine oxidase B
  GPR18                    G protein-coupled receptor 199                                                  PAH       Phenylalanine hydroxylase
  MGLL                     Monoacyl glycerol lipase                                                        SLC6A3    Dopamine transporter (DAT)
  NAPEPLD                  *N*-acyl phosphatidylethanolamine phospholipase D                               SLC8A2    Dopamine transporter (VMAT2)
  NAAA                     N-acylethanolamine acid amidase                                                 TH        Tyrosine hydroxylase
  PPARA                    Peroxisome proliferator-activated receptor α                                    PPP1R1B   Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32)
  PTGS2                    Prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2 (COX-2)             
  PTPN22                   Protein tyrosine phosphatase, nonreceptor type 22                                         
  TRPV1                    Transient receptor potential cation channel subfamily V member 1                          

###### 

Studies included in this work.

  Species            Model                       Region                   Stage[\*](#tf2-1){ref-type="table-fn"}   Systems analyzed               Reference                  GEO accession
  ------------------ --------------------------- ------------------------ ---------------------------------------- ------------------------------ -------------------------- --------------------
  *H. sapiens*       HD donor tissue             CPu, Cb, PfACtx, MCtx    Pre-, Early, Middle, Late                ECS                            Hodges et al. (([@b49])    GSE3790
  CPu                Middle                      ECS                      Hu et al. ([@b54])                       GSE24250                                                  
  HD patients        Peripheral blood            Pre-, Early              ECS and DAS                              Borovecki et al. ([@b14])      GSE1767                    
  Peripheral blood   Middle                      ECS and DAS              Runne et al. ([@b95])                    GSE8762                                                   
  Peripheral blood   Pre-, Early, Middle, Late   ECS                      Lovrecic et al. ([@b67])                 GSE1751                                                   
  ESC                Stem cells                  In vitro                 ECS                                      Feyeux et al. ([@b32])         GSE34201                   
  iPSC               Stem cells                  In vitro                 ECS                                      An et al. ([@b3])              GSE37547                   
  PC12               Immortalized cell line      In vitro                 ECS                                      van Roon-Mom et al. ([@b92])   GSE10581                   
  *M. musculus*      R6/1                        Str, Cb                  Pre-, Early, Middle                      ECS                            Benn et al. ([@b9])        GSE3248
  Str                Middle                      ECS                      Desplats et al. ([@b25])                 None                                                      
  Whole-brain        Early                       ECS and DAS              Hodges et al. ([@b50])                   GSE3621                                                   
  R6/2               Str                         Early                    ECS                                      Benn et al. ([@b9])            GSE3248                    
  Whole-brain        Middle                      ECS                      Morton et al. ([@b77])                   GSE857                                                    
  Str                Middle                      ECS                      Thomas et al. ([@b104])                  GSE857                                                    
  N171-82Q           Whole-brain                 Middle                   ECS                                      Luthi-Carter et al. ([@b69])   None                       
  Hpc, Cb            Early                       ECS                      Valor et al. ([@b106])                   GSE44306, GSE44855, GSE44854                              
  Hpc, Cb            Early                       ECS                      Lopez-Atalaya et al. (2013)              GSE44868                                                  
  YAC128             Str                         Pre-, Early, Middle      ECS                                      Morton et al. ([@b77])         GSE857                     
  Str                Early, Middle               ECS                      Becanovic et al. ([@b8])                 GSE18551, GSE19676, GSE19677                              
  Str                Middle                      ECS                      McConoughey et al. ([@b74])              GSE21237                                                  
  Hdh^Q111/Q111^     Str                         Middle                   ECS                                      Horsch ([@b52])                GSE28232                   
  Str, Cb            In vitro                    ECS and DAS              Fossale et al. ([@b34])                  GSE9038                                                   
  CHL2(Q150/Q150)    Str                         Pre-, Early, Middle      ECS                                      Morton et al. ([@b77])         GSE857                     
                     Hdh^Q92/Q92^                Str                      Pre-, Early, Middle                      ECS                            Morton et al. ([@b77])     GSE857
                     D9-N171-98Q                 Str                      Middle                                   ECS                            Thomas et al. ([@b104])    GSE25232, GSE26317
                     PGC1a^−/−^ Hdh^Q150/Q150^   Str                      Middle, Late                             ECS and DAS                    Cui et al. ([@b21])        GSE5786
                     Ctip2^−/−^                  Str                      Middle, Late                             ECS and DAS                    Arlotta et al. ([@b5])     GSE9330
                     Hdh^Q7/Q20^                 ESC                      In vitro                                 ECS                            Jacobsen et al. ([@b56])   GSE26001
                     Hdh^Q7/Q50^                 ESC                      In vitro                                 ECS                            GSE26001                   
                     Hdh^Q7/Q91^                 ESC                      In vitro                                 ECS                            GSE26001                   
                     Hdh^Q7/Q111^                ESC                      In vitro                                 ECS                            GSE26001                   
                     STHdh^Q111/Q111^            Immortalized cell line   In vitro                                 ECS and DAS                    Lee et al. ([@b64])        GSE9025, GSE19780
                                                 Immortalized cell line   In vitro                                 ECS                            Riva et al. ([@b91])       GSE38000, GSE38001
                     STHdh^Q109/Q109^            Immortalized cell line   In vitro                                 ECS                            Soldati et al. ([@b99])    GSE42107
                     htt-171-82Q                 Immortalized cell line   In vitro                                 ECS and DAS                    Runne et al. ([@b96])      GSE1918, GSE12481
                                                 Immortalized cell line   In vitro                                 ECS                            Martin et al. ([@b72])     GSE39586
  *R. norvegicus*    Transgenic Q51              Whole brain              Pre-, Middle                             ECS                            Nguyen et al. ([@b79])     GSE3790
  ST14A              Immortalized cell line      In vitro                 ECS                                      Thompson et al. ([@b105])      GSE49392                   
  *S. cereviseae*    Yeast                                                In vitro                                 ECS                            Tauber et al. ([@b103])    GSE18644

Pre-, Early, Middle, and Late refer to relative disease stage based on progression of motor dyskinesia in human patients with HD or animal models. For this study in vitro models were categorized as "Early." Cb, cerebellum; CPu, caudate and putamen; DAS, dopamine system; ECS, endocannabinoid system; ESC, embryonic stem cells; Hpc, hippocampus; iPSC, induced pluripotent stem cells; PfACtx, prefrontal association cortex; MCtx, motor cortex; Str, striatum.

For each of the 39 results obtained (Table[2](#tbl2){ref-type="table"}), the publicly available microarray data from each study were collected from the GEO using the GEO DataSets and Profiles tools. Data from two studies were unavailable through GEO and were obtained directly for the manuscripts (Luthi-Carter et al. [@b69]; Desplats et al. [@b25]). The search term used in GEO DataSets and GEO Profiles was "Huntington\*." Filters were added to the search result in GEO Profiles by providing the gene symbol for each gene searched (Table[2](#tbl2){ref-type="table"}) in *Homo sapiens and Mus musculus*, but no filters were placed on organism. GEO Profiles data were searched with the filter "Up/down genes" turned on *and* off to ensure no datasets were missed. All other filters and settings were left on default. The resulting GEO Profiles were then reviewed by hand to ensure they matched the studies collected in the literature search. Expression data for each gene were downloaded from GEO Profiles and subsequently used for analysis and scoring.

Analysis, scoring, and graphical output of the observed change in gene expression
---------------------------------------------------------------------------------

Expression values for each dataset were imported into Microsoft Excel (Microsoft, 2008), organized by gene, and the mean and SEM for each gene for each group within a dataset was calculated. Significance between groups within a dataset was tested via one-way ANOVA followed by Tukey\'s post-hoc test using GraphPad (v. 5.0, Prism). If no significant difference between groups was found, then that dataset was assigned a value of 0. If a significant difference was found, then that dataset was assigned a ranked value between 1 and 5 according to the model used in each dataset, where 1 was assigned for knockout mice that modeled HD but did not express mHtt, 2 for in vitro models of HD, 3 for rodent models of HD, 4 for stem cells derived from HD tissue, and 5 for human HD tissue samples (Kalathur et al. [@b58]). This ranking scheme was adopted and modified from Kalathur et al. ([@b58]), who developed it in their study of changes in signal transduction that occur during HD progression as determined by analysis of data available on the HD research crossroads database (Kalathur et al. [@b58]). We chose to adopt the ranking system of Kalathur et al. ([@b58]) because it is based on phenotypic and/or genetic similarity to the pathophysiology and molecular pathology observed in HD patients. Consequently, human tissue was given the highest value (5) and stem cells derived from patients with HD were given the second highest value (4). The ranked score was then given a positive or negative value if the change in gene expression was increased or decreased, respectively. The sum of the ranked scores from each dataset for each gene was then calculated according to the analysis being done. Sums were then normalized by dividing the number of studies that reported expression for that gene to arrive at the observed change in gene expression (OCGE). For example, the OCGE for *CNR1* shown in Figure[1A](#fig01){ref-type="fig"} was determined by dividing the sum of the ranked values for all studies that reported the levels of *CNR1* transcripts (−63) by the number of studies (27 studies) to arrive at an OCGE of −4.2. The error around the OCGE was determined by calculating the normalized sum of the ranked values for studies that *did not* report expression levels for a given gene (i.e., the upper and lower limit for the OCGE if all studies we examined had reported expression levels for a given gene). Thus, in Figure[1A](#fig01){ref-type="fig"}, 12 studies did not include data on *CNR1* levels and the sum of ranked scores for these studies was 33; therefore, the error was ±2.75. The resulting OCGEs were analyzed using a one-sample *t*-test where *x* was the OCGE for a particular gene, *μ*~0~ was set to 0, *s* was the standard deviation for a particular gene, and *n* was the number of reports for a particular gene (GraphPad Prism v. 5.0). Post-hoc Holm-Bonferroni corrections for multiple testing were conducted for all datasets because multiple genes from multiple datasets were compared in these analyses (GraphPad Prism v. 5.0).

![Transcriptional dysregulation of the ECS in microarray studies of HD. (A, B) Data are represented as the OCGE, which was the sum of the scoring matrix for each gene divided by the number of reports used in to generate that score ± the sum of the scoring matrix for all studies that did not report a change in the expression of each gene. Open boxes denote an OCGE different from 0 (*P *\<* *0.05). (A) Overall changes in gene expression in the CNS. (B) Overall changes in gene expression in the periphery. C--E) Significant OCGE relative to 0 are indicated by color. White: no change; yellow: decreased; light blue: increased. (C) Changes in gene expression in the CNS described according to disease stage. (D) Changes in gene expression in the periphery described according to disease stage. (E) Changes in gene expression in the CNS described according to model.](prp20003-e00104-f1){#fig01}

Observed change in gene expression for overall data in the CNS and peripheral blood, for the ECS and DAS, were graphed on modified Forest plots (Figs.[1A](#fig01){ref-type="fig"}, [B](#fig01){ref-type="fig"} and [2A](#fig02){ref-type="fig"}, [B](#fig02){ref-type="fig"}; GraphPad Prism v. 5.0). CNS data were not subdivided according to brain region. Significance was indicated with open squares. Closed squares indicate no significant difference. OCGEs for data grouped by disease stage (Figs.[1C](#fig01){ref-type="fig"}, [D](#fig01){ref-type="fig"} and [2C](#fig02){ref-type="fig"}, [D](#fig02){ref-type="fig"}) or model (Fig.[1E](#fig01){ref-type="fig"}), were represented as tables (Microsoft Excel, 2008). Disease stage was chosen based on motor symptom severity as described in each study. For the purpose of this study, in vitro data were described as "early." Significance (*P* value) and the number of studies used in each analysis are indicated for each gene. Color indicates the direction of change for each gene such that white indicates no change; yellow indicates a decrease; and blue indicates an increase. Details of the expression of different genes in each of the studies analyzed are provided in Tables S1 (ECS) and S2 (DAS).

![Transcriptional dysregulation of the DAS in microarray studies of HD. (A, B) Data are represented as the OCGE, which was the sum of the scoring matrix for each gene divided by the number of reports used in to generate that score ± the sum of the scoring matrix for all studies that did not report a change in the expression of each gene. Open boxes denote a OCGE different from 0 (*P *\<* *0.05). (A) Overall changes in gene expression in the CNS. (B) Overall changes in gene expression in the periphery. C, D) Significant OCGEs relative to 0 are indicated by color. White: no change; yellow: decreased; light blue: increased. (C) Changes in gene expression in the CNS described according to disease stage. (D) Changes in gene expression in the periphery described according to disease stage.](prp20003-e00104-f2){#fig02}

Results
=======

A meta-analytical approach was used to assemble and evaluate publicly available HD microarray datasets among microarray studies and compare these data to the previously published alternative molecular approaches that quantified changes in mRNA levels. Using defined inclusion criteria, 39 microarray studies assessing ECS gene expression, and 6 microarray studies assessing DAS gene expression were chosen for meta-analyses (Table[2](#tbl2){ref-type="table"}).

The ECS within the CNS
----------------------

In the CNS, the OCGEs for *CNR1*,*GPR55*,*NAPEPLD*,*PTGS2*, and *GDE1* were less than 0 (*P *\<* *0.05, Fig.[1A](#fig01){ref-type="fig"}). The OCGE for *CNR2* was greater than 0 (*P *\<* *0.05, Fig.[1A](#fig01){ref-type="fig"}). The OCGEs for *GPR18, GRP119, TRPV1, PPARA, DAGL, ABDH4, ABDH6, ABDH12, FAAH, MGLL,* and *NAAA* were not different from 0 (Fig.[1A](#fig01){ref-type="fig"}). CNS microarray data were further divided according to the stage of the disease into "pre-symptomatic," "early," "middle," and "late" stage according to the description of motor symptom severity for the HD model used provided in the manuscript corresponding to each dataset (Fig.[1C](#fig01){ref-type="fig"}). In vitro models were categorized as "early." The OCGE was less than 0 during the presymptomatic (*P *\<* *0.05), early (*P *\<* *0.01), middle (*P *\<* *0.001), and late (*P *\<* *0.001) stages for *CNR1;* presymptomatic (*P *\<* *0.05), middle (*P *\<* *0.001), and late (*P *\<* *0.001) stages for *GDE1;* early, middle, and late stages for *PTGS2* (*P *\<* *0.001); presymptomatic and late stages for *GPR55* (*P *\<* *0.001), *PPARA* (*P *\<* *0.05), and *NAPEPLD* (*P *\<* *0.001); and middle stage for *GPR18* (*P *\<* *0.05) (Fig.[1C](#fig01){ref-type="fig"}). Further, the OCGE was greater than 0 during the middle (*P *\<* *0.05) and late (*P *\<* *0.01) stages for *CNR2* and *FAAH* (Fig.[1C](#fig01){ref-type="fig"}).

To identify changes that occur in mouse and in vitro models of HD that recapitulate changes observed in human HD patients, we also conducted a comparison of OCGEs among human datasets, mouse models of HD, and in vitro models of HD for the ECS (Fig.[1E](#fig01){ref-type="fig"}). OCGEs were consistently less than 0 for *CNR1* and *PTGS2* between human HD tissue, mouse, and in vitro models of HD (Fig.[1E](#fig01){ref-type="fig"}). OCGEs were also less than 0 for *PPARA, NAPEPLD,* and *GDE1* between human HD tissue and mouse models of HD (Fig.[1E](#fig01){ref-type="fig"}). OCGE values were greater than 0 for *CNR2* and less than 0 for *PTPN22* in human studies, but not mouse in vitro models of HD (Fig.[1E](#fig01){ref-type="fig"}). Similarly, OCGE values were only greater than 0 for *FAAH* in mouse models of HD (Fig.[1E](#fig01){ref-type="fig"}). Of all the changes in gene expression that have been reported, only change in *CNR1* and *PTGS2* consistently occurred in mouse and in vitro models of HD, but not others. Notably, the increase observed for *CNR2* is not observed consistently across studies, models of HD, and in human HD tissue.

The ECS in peripheral blood samples
-----------------------------------

Three microarrays studies reported on the expression of ECS transcripts in peripheral blood from patients with HD (Table[2](#tbl2){ref-type="table"}). The samples taken from individuals with HD were staged as pre-symptomatic, early-, middle-, or late-symptomatic and compared with control samples from healthy individuals. These studies sought to identify biomarkers of HD onset and progression. We found that the OCGE for the pooled data was less than 0 for *CNR1*, and greater than 0 for *CNR2, GPR55, PPARA, NAPEPLD, PTGS2, GDE1*, and *PTPN22* (*P *\<* *0.05, Fig.[1B](#fig01){ref-type="fig"}). The OCGEs were not different from 0 for *GPR18, GPR119, TRPV1, DAGL, ABDH4, ABDH6, ABDH12, FAAH, MGLL,* and *NAAA* (Fig.[1B](#fig01){ref-type="fig"}). Changes in the levels of *CNR1* and *CNR2* have been extensively documented in the literature, whereas the changes in *GPR55, PPARA, NAPEPLD, PTGS2, GDE1*, and *PTPN22* have not been recognized as consistent in peripheral blood samples from HD patients. Further, when these data were compared with the overall data for the ECS in the CNS (Fig.[1A](#fig01){ref-type="fig"}), *GPR55, NAPEPLD, PTGS2, GDE1,* and *PTPN22* OCGEs are all decreased in the CNS and increased in peripheral blood samples (Fig.[1B](#fig01){ref-type="fig"}). Next, data were subdivided by disease stage. The OCGE was greater than 0 during the presymptomatic and late stages for *CNR2* (*P *\<* *0.001 and *P *\<* *0.05), *PTGS2* (*P *\<* *0.001), *GDE1* (*P *\<* *0.001); and the presymptomatic stage for *GPR55* (*P *\<* *0.001), *PPARA* (*P *\<* *0.01), *NAPEPLD* (*P *\<* *0.001), and *PTPN22* (*P *\<* *0.001) (Fig.[1D](#fig01){ref-type="fig"}). The OCGE was greater than 0 during the early stage for *FAAH* (*P *\<* *0.001) and during the late stage for *CNR1* and *NAAA* (*P *\<* *0.05) (Fig.[1D](#fig01){ref-type="fig"}). By dividing the data according to disease stage, we observed that all changes in gene expression in the peripheral ECS were stage specific. Moreover, the OCGE values for *FAAH* and *NAAA* were not different from 0 in the overall analysis, but were different at specific stages of HD. Therefore, several components of the ECS could be utilized as disease stage-specific biomarkers in HD.

The DAS within the CNS
----------------------

We calculated the OCGE for each gene examined in the DAS in the CNS the six datasets that met our inclusion criteria (Table[2](#tbl2){ref-type="table"}). We found that, in the CNS, the OCGEs for *DRD2*,*TH*,*COMT*,*VMAT2*,*DAT*, and *PPP1R1B* were less than 0 (*P *\<* *0.05, Fig.[2A](#fig02){ref-type="fig"}). The OCGEs for *DRD1*,*DRD3*,*DRD4*,*DRD5*,*PAH*,*DDC*,*DBH*,*MAOA*, and *MAOB* were not different from 0 (Fig.[2A](#fig02){ref-type="fig"}). CNS microarray data were further divided according to disease stage (Fig.[2C](#fig02){ref-type="fig"}). In vitro models were categorized as "early." Only the OCGE for *PPP1R1B* was less than 0 during the early stage (*P *\<* *0.05) (Fig.[2C](#fig02){ref-type="fig"}). The OCGE was less than 0 during the middle and late stages for *DRD2* (*P *\<* *0.001 and *P *\<* *0.01), *VMAT2* (*P *\<* *0.01 and *P *\<* *0.05), and *DAT* (*P *\<* *0.01), middle stage for *DRD3* (*P *\<* *0.05), and late stage for *TH* (*P *\<* *0.01), *DDC* (*P *\<* *0.01), *DBH* (*P *\<* *0.05), and *COMT* (*P *\<* *0.01) (Fig.[2C](#fig02){ref-type="fig"}). Further, the OCGE was greater than 0 during the middle stage for *MAOA* (*P *\<* *0.01) and the late stage for *MAOB* (*P *\<* *0.05) (Fig.[2C](#fig02){ref-type="fig"}). We could not complete a comparison of models of HD for the DAS due to the limited number of studies that reported changes in the DAS. Importantly, we observed a disease stage-specific change in the OCGE for *DRD3*,*DDC, DBH, MAOA,* and *MAOB* where no difference had been observed in the overall analysis.

The DAS in peripheral blood samples
-----------------------------------

Two microarrays studies reported on the expression of DAS transcripts in peripheral blood from patients with HD (Table[2](#tbl2){ref-type="table"}). Samples were taken from individuals with HD prior to motor symptom onset (presymptomatic), or in the early or middle stages of HD and compared with control samples from healthy individuals. The OCGE for the pooled data was less than 0 for *DRD2, DRD3, DRD4, DRD5, TH, DDC, VMAT2, DAT*, and *PPP1R1B*, and greater than 0 for *COMT* (*P *\<* *0.05, Fig.[2B](#fig02){ref-type="fig"}). The OCGEs were not different from 0 for *DRD1, PAH, MAOA,* and *MAOB* (Fig.[2B](#fig02){ref-type="fig"}). Next, data were then subdivided by disease stage. The OCGE was less than 0 during the presymptomatic, early, and middle disease stages for *DRD3* (*P *\<* *0.05 and *P *\<* *0.001); the presymptomatic and early stages for *DRD4*,*TH*, and *DBH* (*P *\<* *0.001); the early stage for *DRD5* and *DDC* (*P *\<* *0.001); and the early and middle stages for *DRD2* and *DAT* (*P *\<* *0.001) (Fig.[2D](#fig02){ref-type="fig"}). Intriguingly, the OCGE was greater than 0 during the presymptomatic stage and less than 0 during the early stage for *PAH* (*P *\<* *0.01) and *COMT* (*P *\<* *0.001 and *P *\<* *0.05) (Fig.[2D](#fig02){ref-type="fig"}). The opposite was found for *VMAT2*, where the OCGE was less than 0 during the presymptomatic stage and greater than 0 during the early stage (*P* \< 0.001 and *P* \< 0.05) (Fig.[2D](#fig02){ref-type="fig"}). The OCGE was less than 0 during all disease stages examined for *PPP1R1B* (*P *\<* *0.05 during the presymptomatic stage, *P *\<* *0.001 during the early and middle stages). Based on these data, the expression of several components of the DAS in peripheral blood samples, are changed in a disease stage-specific manner, which appears to be biphasic for *PAH, COMT*, and *VMAT2*.

Discussion
==========

The main objective of this study was to determine the changes that were consistently observed in the ECS and DAS during HD progression both in the CNS and in peripheral blood in human HD tissue and different models of HD. We used a meta-analytical approach to examine independent studies using an unbiased mathematical approach. In this meta-analysis, publicly available microarray datasets from specific tissues, specific models, and distinct time points in HD progression were compared to the human condition. After the initial development of microarray technologies standards were put in place to provide publicly available curated microarray data (Allison et al. [@b2]). Such data appear in the GEO Profiles database. Within GEO Profiles investigators select subgroups of gene expression data to report; such that not every gene present on a microarray chip appears in the database. Within GEO Profiles we identified 39 microarray studies of the ECS, but only six microarray studies of the DAS included in this analysis. We did not find any publicly available microarray studies of human CNS tissue that examined the DAS.

The ECS in HD
-------------

Of all the changes that are reported in the various microarray studies, only changes in the expression of *CNR1*,*CNR2,* and *FAAH* have been consistently reported and investigated in previous studies (Luthi-Carter et al. [@b68]; Laprairie et al. [@b62], [@b63]). Changes in the expression of *CNR1* have been reported in several HD mouse models using microarray in other studies that were not available in the GEO Profiles datasets (Luthi-Carter et al. [@b68]; Chan et al. [@b18]; Kuhn et al. [@b61]; Benn et al. [@b10]). Similarly, dysregulation of *CNR1* expression has been observed using qRT-PCR and in situ hybridization (Denovan-Wright and Robertson [@b24]; Glass et al. [@b42]). Increased levels of *CNR2* and *FAAH* mRNA have been documented via qRT-PCR and western blot in R6/2 mouse models of HD, ST*Hdh*^Q111/Q111^ cells, and tissue from HD patients (Blázquez et al. [@b13]; Bari et al. [@b7]; Laprairie et al. [@b63]). We observed increased FAAH levels in the late stages of HD, which may indicate increased AEA catabolism (Laprairie et al. [@b63]). Dysregulation of ECS tone may follow changes in the expression FAAH or other anabolic and catabolic cannabinoid enzymes (Bari et al. [@b7]).

The DAS in HD
-------------

Alterations in gene expression of components of the DAS in the basal ganglia have been linked to the pathology of HD in both postmortem human and animal models (El Khoury et al. [@b29]). Changes in the expression of *DRD*~*2*~*, TH, DAT, VMAT2,* and *PPP1R1B* (DARPP-32*)* have been consistently reported in previous studies (Bibb et al. [@b12]; Glass et al. [@b42]; Suzuki et al. [@b102]; Yohrling et al. [@b109]). Reduction in the expression of D~R~D~2~ is well documented in pre- and symptomatic human patients and R6/2 mice models of HD using in situ hybridization, qRT-PCR, autoradiographic, and positron emission tomography (Joyce et al. [@b57]; Richfield et al. [@b90]; Antonini et al. [@b4]; Augood et al.*,* 1997; Glass et al. [@b42]; Bibb et al. [@b12]). Other microarray studies that did not provide publicly available data have also reported lower striatal D~R~D~2~ levels in several HD mouse models including: R6/2, R6/1, N171-82Q, YAC72, and Hdh^Q92/Q92^ mice (Luthi-Carter et al. [@b68]; Chan et al. [@b18]; Kuhn et al. [@b61]; Benn et al. [@b10]). Postmortem studies of late-stage HD patients, R6/2, and YAC128 mice models of HD showed reduced levels of caudate DA and homovanillic acid, the principal DA metabolite (Bernheimer et al. [@b11]; Reynolds and Garrett [@b87]; Kish et al. [@b59]; Reynolds et al. [@b88]; Callahan and Abercrombie [@b16]). Changes in the expression of anabolic enzymes in the CNS that are involved in DA synthesis might play a role in the reduction of DA. The levels of TH, the enzyme that catalyzes the rate-limiting step in the biosynthesis of DA, have been demonstrated previously to decline during late stages of HD progression in HD patients and in R6/2 mice (Yohrling et al. [@b109]). The majority of synaptic DA is cleared by DAT and VMAT2. Similarly to the microarray studies, previous analysis of postmortem brains from late-stage HD patients has shown reduced striatal expression of DAT and VMAT2 using autoradiography (Suzuki et al. [@b102]). Reduction in DARPP-32 expression was previously observed in postmortem human HD and R6/2 mice using immunohistochemistry (Bibb et al. [@b12]; van Dellen et al. [@b23]).

Comparing changes in the ECS and DAS between mouse models of HD
---------------------------------------------------------------

The data presented here indicate that no single gene in the ECS was consistently up- or downregulated in all mouse models included in these analyses (Table S1). The most consistently observed change among ECS genes was downregulation of *CNR1* in 81% of studies utilizing mouse models of HD. *GPR18, GPR55,* and *PTGS2* levels were lower in 28% of studies, *PPARA* levels were lower in 21% of studies, *NAPEPLD* and *GDE1* levels were lower in 12% of studies, and *FAAH* levels were higher in 12% of studies (Table S1). Among genes analyzed in the DAS, *DRD2, DRD3, DAT,* and *PPP1R1B* were consistently downregulated in HD samples (Table S2). However, the limited size of this dataset means that these observations are difficult to interpret. Interstudy variability also existed between mouse models of HD. For example, *FAAH* was reported as upregulated in some studies of R6/1 mice (Benn et al. [@b9]; Desplats et al. [@b25]), but not others (Hodges et al. [@b50]). Similarly, *PTGS2* and *GDE1* were only downregulated in R6/1 mice and no other model examined. Some of the models used in these datasets may not have been old enough to display HD-like transcriptional dysregulation, as previous reports have suggested knock-in models of HD do not display transcriptional dysregulation until later in disease presentation (Kuhn et al. [@b61]). Similarly, the novel zQ175 knock-in mouse model of HD displays a subset of the transcriptional abnormalities observed in R6/1 and R6/2 mice, including reduced *CNR1* expression, during that time of motor symptom onset rather than prior to motor symptom onset (Menalled et al. [@b75]). Although no microarray analyses have been done with zQ175 mice, this mouse model exhibits metabolic, behavioral, and motor deficits over a longer time course than the rapidly degenerating R6 lines, suggesting this model may be most useful for the study of long-term behaviors and phenotypes (Menalled et al. [@b75]). These data demonstrate that variability in the pattern of transcriptional dysregulation exists between different mouse models of HD. While certain changes, such as decreased levels of *CNR1*, are relatively robust, other changes may be model specific and more readily detected in aggressive models of HD, such as R6/1 and R6/2 mice.

Comparing data from mouse models of HD to human tissue studies
--------------------------------------------------------------

One major use of these data is determining the predictive power of animal models of HD in the rational development of therapies for patients suffering from HD. Our analysis revealed that, in general, changes in *CNR1*,*PPARA, NAPEPLD, PTGS2,* and *GDE1* were consistent between mouse and human studies. This comparative analysis is not possible for the DAS due to the limited size of the dataset. When individual mouse models are compared to the observations made in human tissue studies, all models examined (Table[2](#tbl2){ref-type="table"}) reported the well-characterized downregulation of *CNR1*, but only the R6/1 and R6/2 mouse models, with some exceptions, displayed similar patterns of gene expression to those observed in human datasets (Table S1). The strong correlation between the genome-wide pattern of transcriptional dysregulation in R6 mouse models of HD and human tissue samples has been noted elsewhere (Kuhn et al. [@b61]). The absence of correlation in our data between mouse models of HD and human HD tissue samples may be the result of the small number of genes selectively analyzed (Kuhn et al. [@b61]). Here, we demonstrate that the pattern of gene expression for the ECS is largely similar between R6 mouse models and samples from human HD tissue and largely dissimilar between other mouse models of HD compared to human HD tissue. It is important to note that while no single mouse model of HD can be considered the most valid tool for assessing disease progression or the efficacy of novel therapeutics. The animal model must be carefully chosen as the most suitable tool to answer the question being posed.

Changes in the ECS and DAS that occur in peripheral blood may be useful as biomarkers in HD
-------------------------------------------------------------------------------------------

HD is often described as a neurodegenerative disease rather than a disease that affects the whole body. The data presented here demonstrate that changes in gene expression occur in the peripheral blood in a disease stage-specific manner to an equal or greater extent than in the CNS. It is important to note that while changes in gene expression in peripheral blood may not occur in the CNS, but can still be followed as biomarkers of disease progression. Although the pathological implications of these changes are unknown, novel stage-specific biomarkers for HD could improve the selection and efficacy of therapies for the treatment of HD (Runne et al. [@b95]).

Targeting the endocannabinoid and dopamine systems in the treatment of HD
-------------------------------------------------------------------------

There are currently no treatments available to cure or delay the progression of HD. Studies in animal and in vitro models of HD suggest that certain CB~1~ agonists may reduce hyperkinetic movement in HD and promote the survival of medium spiny projection neurons (Dowie et al. [@b26], [@b27],[@b28]; Blázquez et al. [@b13]). One clinical trial using nabilone, a CB~1~/CB~2~ agonist, has reported minor, but significant, improvements in chorea and irritability in HD patients (Curtis et al. [@b22]). Another clinical trial exploring the beneficial effects of Sativex (THC and cannabidiol) for the treatment of chorea in HD has recently been completed although the results have not yet been published (National Institutes of Health). Two other therapeutic targets in the ECS are FAAH and CB~2~. Because FAAH levels are elevated late in HD, FAAH inhibitors may be able to restore ECS functionality in HD via CB~1~ (Bari et al. [@b7]; Laprairie et al. [@b63]). Therefore, several components of the ECS offer potential therapeutic targets for the treatment of HD.

Existing pharmacological treatments only alleviate motor and cognitive symptoms of HD (reviewed in Pidgeon and Rickards [@b85]). Treatments targeting the DAS have to be chosen according to the stage of the disease because DA levels are increased early in HD pathogenesis and decrease as the disease progresses (Chen et al. [@b19]). Clinical evidence also suggests that D~R~D~2~ antagonists, such as haloperidol, olanzapine, risperidone, quetiapine, and ziprasidone, might be beneficial to treat chorea, changes in mood, and behavior during early stage of HD (reviewed in Pidgeon and Rickards [@b85]). Targeting other components of the DAS for the treatment of HD has also been investigated. For example, tetrabenazine, the only drug approved for treatment of chorea in HD, acts as a VMAT inhibitor and D~R~D~2~ antagonist (Mestre and Ferreira [@b76]). During late stages of the disease drugs that increase DA levels, such as bromocriptine, lisuride. and aripiprazole, may alleviate akinesia (Mestre and Ferreira [@b76]). MAOA and MAOB expression is also elevated in the basal ganglia during the latter stages of HD (Richards et al. [@b89]). Elevation of DA via MAOB inhibition may, therefore, have beneficial effects during the late stages of HD (Pidgeon and Rickards [@b85]). However, contradictory clinical results have been reported for these drugs, which demonstrate the time-dependent changes that occur in the DAS as the disease progresses (Chen et al., 2013).

In situ hybridization studies assessing mRNA expression and immunohistochemistry studies assessing protein expression have shown that CB~1~ and D~R~D~2~ are colocalized in the GABA-ergic medium spiny neurons projecting from the striatum to the globus pallidus, as well as on the axon terminals at the globus pallidus (Gerfen et al. [@b39]; Mailleux and Vanderhaeghen [@b70]; Hermann et al. [@b47]; Matyas et al. [@b73]; Pickel et al. [@b84]). Colocalization of these receptors in the basal ganglia may allow for bidirectional regulation between the ECS and DAS through the formation of functional heterodimers (Fernandez-Ruiz et al. [@b31]). D~R~D~2~ modulates release of AEA in the dorsal striatum (Giuffrida et al. [@b40]), and facilitates endocannabinoid-mediated long-term synaptic depression of GABA-ergic neurons (Pan et al. [@b82]). In addition, receptor agonists may modulate subcellular localization, receptor expression and homo- and heterodimer ratios of CB~1~ and D~R~D~2~ (Przybyla and Watts [@b86]). Given these interactions between the ECS and the DAS, drugs that effect one system will likely effect the other (Wiley et al. [@b108]), yet the consequences of cannabinoid treatment on dopaminergic tone or DA treatment on endocannabinoid tone are unknown in healthy individuals, let alone people suffering from HD. Moreover, the possible recreational or illicit use of *cannabis* by HD patients may alter the efficacy of drugs targeting the DAS. Therefore, a better understanding of the relationship between the ECS and DAS is not only important in and of itself, but it is also directly applicable to HD and the design of therapies for HD.

Conclusions
===========

The consolidated data presented here provide a high-level summary of changes that occur in the ECS and DAS--two systems whose functionality is dysregulated in HD. These data provide a point of consensus for future studies where the ECS and DAS are targeted for the management of HD in different models, stages of disease progression, and in the human condition. This meta-analysis is also a useful reference for future microarray array work in HD. Finally, given the lack of DAS data available in GEO profiles, future studies should include DAS data in publicly accessible microarray datasets regardless of how these genes are affected in HD, and regardless of whether these genes are affected, particularly where preclinical therapies are tested in disease models.

Because HD affects gene expression in the ECS and DAS, the efficacy of drugs that target these systems may depend on the disease stage-specific tone of the system being targeted. Moreover, dopaminergic drugs and cannabinoids could affect the expression of their target genes, which may or may not be therapeutically desirable. But perhaps the greatest gap in our knowledge is the relationship between the ECS and DAS in the CNS of healthy individuals and patients suffering from HD. Characterization of the crosstalk that occurs between the ECS and DAS may lead to the development of novel therapeutics that exploit the connections and commonalities between these systems.
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2-AG

:   2-arachidonyl glycerol

ABDH

:   abhydrolase domain-containing protein

AEA

:   anandamide

CB~1~

:   type 1 cannabinoid receptor

CB~2~

:   type 2 cannabinoid receptor

CNS

:   central nervous system

COMT

:   catechol-[o]{.smallcaps}-methyl transferase

COX-2

:   cyclooxygenase-2

CPu

:   caudate and putamen

DAGL

:   diacyl glycerol lipase

DARPP-32

:   dopamine and cyclic AMP-regulated phosphoprotein 32 kDa

DAS

:   dopaminergic system

DAT

:   dopamine transporter

DBH

:   dopamine *β*-hydroxylase

DDC

:   DOPA decarboxylase

D~R~D~X~

:   dopamine receptor type x

ECS

:   endocannabinoid system

FAAH

:   fatty acid amide hydrolase

GDE1

:   glycerophosphodiester phosphodiesterase 1

GEO

:   gene expression omnibus

HD

:   Huntington\'s disease

MAO

:   monoamine oxidase

MGLL

:   monoacyl glycerol lipase

mHtt

:   mutant huntingtin protein

NAAA

:   *N*-acylethanolamine acid amidase

NAPE-PLD

:   *N*-acyl phosphatidylethanolamine phospholipase D

OCGE

:   observed change in gene expression

PAH

:   phenylalanine hydroxylase

PPAR*α*

:   peroxisome proliferator-activated receptor *α*

PTPN22

:   protein tyrosine phosphatase nonreceptor type 22

THC

:   Δ^9^-tetrahydrocannabinol

TH

:   tyrosine hydroxylase

TRPV1

:   transient receptor potential vanilloid 1

VMAT

:   vesicular monoamine transporter
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**Table S1.**Detailed summary of OCGE values by study for the endocannabinoid system. GEO DataSets Accession Numbers are listed below each species. GEO Profiles data were used in data analyses. Significant OCGEs relative to 0 are indicated by color. White: no change; yellow: decreased; light blue: increased; black: no data.

**Table S2.** Detailed summary of OCGE values by study for the dopaminergic system.GEO DataSets Accession Numbers are listed below each species. GEO Profiles data were used in data analyses. Significant OCGEs relative to 0 are indicated by color. White: no change; yellow: decreased; light blue: increased; yellow and light blue: the study reports disease stage-specific changes in gene expression.
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